Overcoming poor permeability: Translating permeation enhancers for oral peptide delivery

Drug Discovery Today: Technologies

Volumn 9, Issue 2, 2012, Pages

  Maher, Sam ^a   Brayden, David J ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; ALKYLMALTOSIDE; AMINO ACID DERIVATIVE; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BILE SALT; CAPCITONIN; CAPSULIN; CHOLIC ACID; CITRIC ACID; DESMOPRESSIN; DICLOFENAC; EDETATE SODIUM; ELIGEN; ENTERIPEP; EXCIPIENT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEPARIN DERIVATIVE; INSULIN; INTRAVAIL; MALTOSE; MEDIUM CHAIN ACYLGLYCEROL; N (5 CHLOROSALICYLOYL) 8 AMINOCAPRYLIC ACID; OCTANOIC ACID; OCTAPEPTIDE; OCTREOLIN; OCTREOTIDE; ORACAL; PARATHYROID HORMONE; PENETRATION ENHANCING AGENT; RECOMBINANT HUMAN INSULIN; SALCATONIN; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; [N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLIC ACID];

ARTICLE; CELL MEMBRANE; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; ENTERIC COATED TABLET; HUMAN; HYDROPHILICITY; INTESTINE EPITHELIUM; MACROMOLECULE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS;

EID: 84866723704     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2011.11.006     Document Type: Review

References (59)

1. Chien, J.Y. and Ho, R.J. (2008) Drug delivery trends in clinical trials and translational medicine. J. Pharm. Sci. 97, 2543-2547
2. Walsh, G. (2009) Market development of biopharmaceuticals. Genet. Eng. Livest.: New Appl. Interdiscipl. Perspect. 34, 69-89
3. Vlieghe, P. et al. (2010) Synthetic therapeutic peptides: science and market. Drug Discov. Today 15, 40-56
4. Swenson, S.E. and Curatolo, W.J. (1992) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8, 39-92
5. Amidon, G.L. et al. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420
6. Moen, M.D. (2009) Topical diclofenac solution. Drugs 69, 2621-2632
7. Bernstein, G. (2008) Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin. Drug Deliv. 5, 1047-1055
8. Maher, S. et al. (2009) Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427-1449
9. Baluom, M. et al. (2000) Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharm. Res. 17, 1071-1076
10. Lee, Y.H. and Sinko, P.J. (2000) Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 42, 225-238
11. Sinko, P.J. et al. (1999) Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm. Res. 16, 527-533
12. Stern, W. and Gilligan, J.P. [Unigene Laboratories] (1999) Oral salmon calcitonin pharmaceutical products. USP 5912014
13. http://www.tarsatherapeutics.com/news/091811.html (accessed November 10th, 2011)
14. Muranishi, S. (1990) Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7, 1-33
15. Porter, C.J. et al. (2007) Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6, 231-248
16. Gookin, J.L. et al. (2002) Inducible nitric oxide synthase mediates early epithelial repair of porcine ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G157-G168
17. Blikslager, A.T. et al. (2007) Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 87, 545-564
18. Goldberg, M. and Gomez-Orellana, I. (2003) Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2, 289-295
19. Brayden, D. et al. (1997) Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm. Res. 14, 1772-1779
20. Hess, S. et al. (2005) Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur. J. Pharm. Sci. 25, 307-312
21. Karsdal, M.A. et al. (2011) Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J. Clin. Pharmacol. 51, 460-471
22. Walsh, E. et al. (2011) Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET1). Ther. Deliv. 12, 1595-161010.4155/TDE.11.132
23. Hardee, G.E. et al. (2008) Routes and formulation for the delivery of antisense oligonucleotides. In Antisense Drug Technology Principle, Strategies and Applications (Crooke, S.T., ed.), pp. 217-236, CRC Press
24. Tillman, L.G. et al. (2008) Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97, 225-236
25. Salama, P. et al. [Lando and Anastasi] (2010) Pharmaceutical combinations and related methods of delivery. USP Application 01056275A1
26. Atsmon, J. et al. (2010) Octreolin™, a safe oral alternative for parenteral octreotide treatment; phase 1 study results. 14th European NeuroEndocrine Association Congress, Liege, Belgium, 22-25 September (abstract OC-6.5)
27. Wang, X. et al. (2010) Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate. Ther. Del. 1, 75-82
28. Sharma, P. et al. (2005) Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60, 884-893
29. New, R. [Axcess Limited] (2004) Absorption enhancers. USP 7303762
30. Storey, R.A. (2009) Benzyl alcohol. In Handbook of Pharmaceutical Excipients (6th edn) (Rowe, R.C., Skeskey, P.J., Quinn, M.E., eds), pp. 64-66, Pharmaceutical Press
31. Luzio, S.D. et al. (2010) The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes. Metab. 12, 82-87
32. Kidron, M. [Oramed Ltd.] (2010) Methods and compositions for oral administration of peptides. USP 0014247
33. Kidron, M. [Oramed Ltd.] (2011) Methods and compositions for oral administration of exenatide. USP Application 0046053
34. Eldor, R. et al. (2010) Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects. Diabetes Obes. Metab. 12, 219-223
35. Eldor, R. et al. (2010) A single blind, two-period study to assess the safety and pharmacodynamics of an orally delivered GLP-1 analog (Exenatide) in healthy subjects. 70th Meeting of the American Diabetes Association, Florida, USA, 25-29 June (abstract 6-LB)
36. LeCluyse, E.L. and Sutton, S.C. (1997) In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement. Adv. Drug Deliv. Rev. 23, 163-183
37. Thassu, D. (2009) Edetic acid. In Handbook of Pharmaceutical Excipients (6th edn) (Rowe, R.C., Skeskey, P.J., Quinn, M.E., eds), pp. 247-250, Pharmaceutical Press
38. Lanigan, R.S. and Yamarik, T.A. (2002) Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA. Int. J. Toxicol. 21 (Suppl. 2), 95-142
39. Maggio, E.T. (2006) Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv. 3, 529-539
40. Maggio, E.T. and Grasso, P. (2011) Oral delivery of octreotide acetate in Intravail1 improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul. Pept. 167, 233-238
41. Lee, D.W. et al. (2010) Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration. Regul. Pept. 160, 129-132
42. Arnold, J.J. et al. (2004) Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J. Pharm. Sci. 93, 2205-2213
43. Kondoh, M. et al. (2008) Targeting tight junction proteins - significance for drug development. Drug Discov. Today 13, 180-186
44. Johnson, P.H. et al. (2008) Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov. Today 13, 261-267
45. Deli, M.A. (2009) Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 1788, 892-910
46. Kondoh, M. et al. (2005) A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 67, 749-756
47. Suzuki, H. et al. (2011) A toxicological evaluation of a claudin modulator, the C-terminal fragment of Clostridium perfringens enterotoxin, in mice. Pharmazie 66, 543-546
48. Salama, N.N. et al. (2006) Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58, 15-28
49. Gutzeit, A. et al. (2010) Feasibility of small bowel flow rate measurement with MRI. J. Magn. Reson. Imaging 32, 345-351
50. Varum, F.J. et al. (2008) Mucoadhesion and the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 25, 207-258
51. Froehlich, J.M. et al. (2005) Small bowel motility assessment with magnetic resonance imaging. J. Magn. Reson. Imaging 21, 370-375
52. Schiller, C. et al. (2005) Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22, 971-979
53. Fetih, G. et al. (2005) Improvement of absorption enhancing effects of ndodecyl- beta-D-maltopyranoside by its colon-specific delivery using chitosan capsules. Int. J. Pharm. 293, 127-135
54. Van den Mooter, G. (2006) Colon drug delivery. Expert Opin. Drug Deliv. 3, 111-125
55. O'Brien, P.J. et al. (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604
56. McDonel, J.L. (1986) Toxins of Clostridium perfringens types A, B, C, D, and E. In Pharmacology of Bacterial Toxins (Dorner, F. and Drews, H., eds), pp. 477-517, Pergamon Press
57. Argenzio, R.A. et al. (1988) Restitution of barrier and transport function of porcine colon after acute mucosal injury. Am. J. Physiol. 255 (Pt 1), G62-G71
58. Wallace, J.L. (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol. Rev. 88, 1547-1565
59. Leonard, T.W. et al. (2006) Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3, 685-692